CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients appear to be more benign and most likely originate from generic perturbations that affect the pre-existing pool of memory CD8+ T-cells (Fig. 7B).